SELLAS Life Sciences Group, Inc.

Analysis for Ticker: SLS

SELLAS Life Sciences Group Inc is a clinical stage biopharmaceutical company that claims to develop cancer treatments like Galinpepimut-S and SLS009. In reality, the company has burned through 275$ million since its inception without ever selling a single product. Its actual business model is not medicine, but the continuous manufacturing and selling of its own stock to pay its bills. Think of it like a bakery that never sells bread but survives by constantly selling pieces of the oven to neighbors who hope a loaf will eventually appear. The math is a disaster because the bakery is almost entirely owned by people who are just waiting to sell their piece of the oven to the next person, while the people running the bakery take the cash for themselves.